Innate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Update

Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 100 shares, a drop of 99.5% from the May 15th total of 21,000 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. Approximately 0.0% of the shares of the company are sold short.

Innate Pharma Stock Performance

OTCMKTS IPHYF remained flat at $1.45 on Thursday. The firm has a fifty day simple moving average of $1.49 and a 200 day simple moving average of $2.26. Innate Pharma has a twelve month low of $1.45 and a twelve month high of $1.76.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.